Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - SALIX PHARMACEUTICALS LTD | d809788dex991.htm |
| EX-99.2 - EX-99.2 - SALIX PHARMACEUTICALS LTD | d809788dex992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 21, 2014
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
| Delaware | 000-23265 | 94-3267443 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 8510 Colonnade Center Drive | ||
| Raleigh, North Carolina | 27615 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (919) 862-1000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
Data Presentation at American College of Gastroenterology 2014 Annual Scientific Meeting
On October 21, 2014, Salix Pharmaceuticals, Ltd. (the “Company”) announced that Dr. Anthony Lembo of Beth Israel Deaconess Medical Center would present the results of TARGET 3, the Company’s Phase 3 retreatment study of rifaximin 550 mg for IBS-D, in a late-breaking podium presentation at the American College of Gastroenterology 2014 Annual Scientific Meeting. A copy of the press release is attached hereto as Exhibit 99.1.
Announcement of Date for Third Quarter 2014 Earnings Release and Conference Call
On October 23, 2014, the Company issued a press release announcing that it will report third quarter 2014 financial results following the close of the U.S. financial markets on Thursday, November 6, 2014. The Company will also host a conference call at 4:30 p.m. ET on that date relating to its third quarter 2014 financial performance. A copy of the press release is attached hereto as Exhibit 99.2.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit |
Description | |
| 99.1 | Press release, dated October 21, 2014. | |
| 99.2 | Press release, dated October 23, 2014. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| October 23, 2014 | SALIX PHARMACEUTICALS, LTD. | |||||
| By: | /s/ Timothy J. Creech | |||||
| Timothy J. Creech | ||||||
| Senior Vice President, Finance and Administrative Services | ||||||
EXHIBIT INDEX
| Exhibit |
Description | |
| 99.1 | Press release, dated October 21, 2014. | |
| 99.2 | Press release, dated October 23, 2014. | |